Semaglutide vs Tirzepatide: What’s the Difference?
Almost every GLP-1 (glucagon-like peptide) medicine available in India contains semaglutide or tirzepatide as the active ingredient. Medicines containing semaglutide - that are, Ozempic, Wegovy and Rybelsus - act only on one gut-hormone pathway (GLP-1 receptor) whereas medicines containing tirzepatide, Mounjaro and Yurpeak, act on two pathways, which are the GLP-1 receptor and GIP (glucose-dependent insulinotropic polypeptide). Amongst these, one medicine is not considered more beneficial than the other, and the choice depends on several factors like their uses, form, how you tolerate them, and their price. Ultimately, your doctor can decide which medicine can be the best fit for you by assessing these.1
Because the same active ingredient can come under different brand names, this page will compare only the active ingredients. Understanding the ingredients will help in assessing the different branded medicines available. This is an educational page, and it does not prioritise one molecule over the other.
Prescription: All semaglutide and tirzepatide medicines are Schedule H medicines, which indicates that a doctor's prescription is mandatory to use these.
GLP-1 medicines are prescription-only. A doctor can tell you whether one is appropriate for you and at what dose.
Consult a doctor Or take the eligibility self-checkSemaglutide vs tirzepatide
Verification of the current price from the product page is advised before ordering. During 2025-26, the price of branded semaglutide was revised more than once, so the actual price may vary from the range of prices shown. To get more information about semaglutide and tirzepatide, please refer to the semaglutide molecule page and the tirzepatide molecule page.
How semaglutide and tirzepatide work
Both molecules act by mimicking the incretin or gut hormones that are released after a meal and are involved in controlling blood sugar and appetite. The major differences lie in the number of hormonal pathways they are involved in and how this helps in reducing blood sugar.
It is a GLP-1 receptor agonist; it acts on a single pathway. When blood sugar is high, it activates the GLP-1 receptors that stimulate the pancreas to release insulin (blood sugar reducing hormone) and reduce glucagon (sugar raising hormone). It is also involved in slowing down how quickly the stomach empties and reduces appetite, which can induce a feeling of fullness sooner and for longer. This GLP involved single pathway is enough in reducing blood sugar in type 2 diabetes cases. This same mechanism is followed in Wegovy, in which semaglutide is used in higher dosages targeting weight loss along with the control of blood sugar.7,8
It is a dual GIP and GLP-1 receptor agonist; it acts on two pathways. This molecule activates both GLP-1 and GIP. GIP is also a type of incretin hormone which is involved in insulin release along with the actions on fat metabolism.9 Here, it engages an additional gut-hormone pathway rather than one when compared to semaglutide.
Semaglutide and tirzepatide are two different molecules and are not two names of the same drug. This difference can show up in the strength ladders (semaglutide dose can vary from fractions of a milligram up to 2.4 mg and tirzepatide can range from 2.5 mg to 15 mg). Due to this, converting one to the other at the same doses are not recommended. These two have separate clinical-trial programmes, which is explained next.
What the trials suggest
Each molecule has its own evidence base. Semaglutide for weight management was studied in the STEP programme5 and for diabetes in the SUSTAIN programme, whereas tirzepatide was studied in the SURMOUNT programme4 for weight management and the SURPASS6 programme for diabetes management. Both could differentiate the average results compared to the placebo effects in their respective studies, which is the basis for their regulatory approvals in India and elsewhere.
The most directly relevant evidence here is SURMOUNT-5, a head-to-head trial that compared tirzepatide against semaglutide for weight management3. In that study, tirzepatide showed a greater average weight reduction than semaglutide.
When selecting a molecule, certain points need to be considered, and your doctor will assess all these and decide which one would suit you better:
These are the average results across a trial population. Individual response may vary, and a trial output might not predict how each person would respond.
“Greater average weight reduction” is one among several outcomes. How much a person can tolerate (tolerability), the intention of usage, other underlying health conditions, cost and long-term effects all need to be considered.
The result in a head-to-head trial is evidence about the molecules in a specific clinic design, and it should not be a reason for self-medication, assuming that one is better for you than the other.
Cost in India
Cost can vary considerably between semaglutide and tirzepatide, particularly because generic semaglutide is now available in India.
It now possesses the widest price range in the category. Its patent expired in India on 20 March 2026, which led to the production of 26+ generic brands; for some, the cost ranges from around ₹350/week10 (for example, Natco’s Semanat), which is the most affordable way into GLP-1 therapy. The brand drug Rybelsus tablets cost ranges from about ₹2,972 for a strip of 10 (3 mg), Ozempic at roughly ₹5,660-₹9,100 a month after the August 2026 price cut, and Wegovy from about ₹5,660 a month at the starter strength up to around ₹16,400 for the 2.4 mg pen.
It has no generic in India yet, so only branded options are available. Mounjaro is sold as single-dose vials from ₹3,281 (2.5 mg/0.5 ml). The KwikPen, which holds four weekly doses, is available from ₹13,125 (2.5 mg) up to about ₹25,781 at the highest strengths. Yurpeak, the Cipla-distributed second brand of the same molecule, is priced similar to the KwikPen, indicatively ₹13,125 - ₹25,781.
When comparing, at the initial level, semaglutide is by far the cheaper molecule because of generics and at the branded-pen level, both overlap. The specific strength you are being prescribed is the matter to be taken into consideration, at today’s rate. You can compare the prices on strength basis in Mounjaro price, Yurpeak price, Ozempic price, Wegovy price and Rybelsus price.
Note: PharmEasy dispenses only 100% genuine, cold-chain-shipped medicines from licensed pharmacies. Counterfeit GLP-1 pens have been reported in India (2026), so purchasing only against a prescription from a licensed pharmacy and checking the pack is recommended.
Side effects of semaglutide and tirzepatide
The side effects of both molecules mostly include digestive symptoms for most people, especially in the first weeks and after each dose increase. Nausea, diarrhoea, vomiting, constipation and indigestion are the commonly reported ones7,8,9. They can become milder as the body gets used to the medicine, and for the same reason doctors usually start in low doses and slowly increase to improve tolerability. This is applicable whether the molecule is delivered as a weekly injection or as a daily tablet, as in Rybelsus.
In clinical setting, the side effect frequency or severity of semaglutide and tirzepatide may depend upon individual factors, the brand and the dose used.
Seek medical help right away if you have severe or persistent stomach pain (a sign of possible pancreatitis), signs of an allergic reaction, or symptoms of very low blood sugar (shakiness, sweating, confusion).
None of these medicines should be used if you have a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, and in such cases medical supervision is mandatory. For the management of early side effects or any related advice, consulting your doctor is advised.
When might each medicine be considered?
The choice between semaglutide and tirzepatide depends on factors such as the condition being treated, your other medicines, treatment goals, preferences, and cost. These examples are for general information only and are not recommendations. Your doctor can help you decide which treatment is appropriate for you.
Both medicines are recommended. Semaglutide as Ozempic (weekly injection) or Rybelsus (daily tablet), and tirzepatide as Mounjaro or Yurpeak (weekly injection), are approved in India for type 2 diabetes. Your doctor can check your blood-sugar control, other medicines and preferences and can decide the best medicine.
The on-label drugs for weight loss are semaglutide as Wegovy and tirzepatide as Mounjaro or Yurpeak. Ozempic and Rybelsus are not approved for weight loss in India. Typically, GLP-1 therapy may be given when BMI is ≥30, or ≥27 with a weight-related condition such as high blood pressure or sleep apnoea is present2. However, self-medication or dosage changes without a proper consultation might be dangerous to your health. Your doctor can decide the appropriate medicine for you.
Only semaglutide comes as an oral tablet in India, which is Rybelsus, taken once daily on an empty stomach, and approved for type 2 diabetes only. Tirzepatide is available only as an injection. Your doctor can decide the appropriate medicine for you.
Semaglutide has a lower price in starting doses because of generics (from ₹350/week)10; tirzepatide is branded-only for now. But the strength you are prescribed and how long you stay on treatment decide the cost more than the starting dose price. Your doctor can decide the appropriate medicine for you.
The SURMOUNT-5 head-to-head trial showed a greater average weight reduction with tirzepatide than semaglutide3. This shows only the trial outputs; however, individual responses, tolerability, approved use, availability and cost are also involved in the variation of results. Only your doctor can decide the appropriate medicine for you.
If you are unsure of which molecule or which brand to choose, please consult a doctor; only a doctor can tell you whether a GLP-1 drug suits your health and issue prescription for the right medicine if needed.
Consult a doctorEducational tools to help you prepare for a conversation with your doctor. None of them prescribe or recommend a medicine.
FAQs
Not sure whether semaglutide or tirzepatide is right for you? Consult a doctor as they can assess your health, discuss the treatment options available in India, and prescribe the most appropriate medicine (if it is suitable for you). You can also explore the brands on our semaglutide and tirzepatide molecule pages.
Consult a doctorReferences
The information provided in this GLP-1 Library is intended solely to educate and inform users about GLP-1 medicines, their uses, benefits, risks, and other relevant considerations. The purpose of this content is to help users make informed decisions and have meaningful discussions with their healthcare professional. PharmEasy does not intend to promote or recommend any specific medicine, brand or treatment.
The information provided is for general informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment, and should not be considered a substitute for consultation with a qualified doctor or other healthcare professional. Before starting, stopping, or changing any medication or treatment, please consult your doctor or qualified healthcare professional. Your doctor can assess your individual health needs and determine whether a GLP-1 medicine is appropriate for you.